Multiple system atrophy (MSA) is a sporadic multisystem progressive disorder characterized by autonomic failure, with orthostatic hypotension (OH), neurogenic bladder and erectile dysfunction, cerebellar ataxia, corticospinal dysfunction, and parkinsonism that may be poorly responsive to levodopa.
1,2 A major clinical dilemma is whether a patient with parkinsonism has Parkinson disease (PD) or MSA, as the prognosis of MSA is much worse. Autonomic involvement is common in PD but is more variable in severity than MSA.
3-5 Mild OH is relatively common in PD and occasionally severe OH can occur.
6,7 In retrospective studies from the Mayo Clinic, we reported that, when quantitative methods were used, the severity and distribution of autonomic deficits appear to distinguish MSA from PD.
4,5 In contrast to MSA, which is predominantly a preganglionic disorder, autonomic pathology in PD is primarily postganglionic,
8 which can be explored in autonomic function tests. Postganglionic adrenergic neuropathy forms the basis of neuroimaging studies of the postganglionic axons of the heart with iodine-123 metaiodobenzylguanidine or other postganglionic adrenergic markers suitable for positron-emission tomography, whereas uptake is markedly reduced or absent in PD and usually normal in MSA.
9-13